

Current as of August 29, 2025

Keyword Index

#


There were no keywords in this range.

A

Acinar Cell Carcinoma	B058
acinar cell signaling	A057
ACT	A068
Actin cytoskeleton dynamics	A109
Activating Transcription Factor 4 (ATF4)	A101
Activin A Signaling	A035
ADM	A036, B048, B060
African patients	A039
aging	B075
AI	B073
Altered RNA splicing	A004
Alternating Therapy	A072
androgens	A090
Antigen presentation; Immune vasion; Dormancy	A014
antisense oligonucleotides	B033
apoptosis	B022
Apoptosis	B023
Architecture	B121
ATF4	A007
ATM, theranostic, TRA RPT	A107
Autophagy and Lysosome	A022
Axl	A083
axonal guidance	B079

B

B7H3	A075
Basal-like PDAC	A028
Bioinformatics	A052
biomarker	B066, B112
Biomarker	B062
biomarkers	A008, A126, B067



**ADVANCES IN PANCREATIC CANCER
RESEARCH – EMERGING SCIENCE
DRIVING TRANSFORMATIVE SOLUTIONS**

September 28–October 1 | Boston, MA

AACR

American Association
for Cancer Research®

2505001F

biophysics	A049
BKT300	A056
Blinded Biomarker Validation	B070
Bmi1	B048
BRCA2 mutated PDAC	B093
bystander effect	A124


C

CA19-9	A104
CA-4948	A069
cachexia	A008
Cachexia	A113
Cachexia, PDAC, Metabolism	B049
CAF	B121
CAF/ECM functional units	A054
CAF: Netrin-G family proteins	A054
Cancer associated cachexia	A005
cancer associated fibroblasts	B079
Cancer associated fibroblasts	A094
Cancer Associated Fibroblasts	B046
Cancer cell plasticity	B108
Cancer cell secreted Hsp70	B016
Cancer cell state	B103
Cancer Hallmarks; PDAC; Neutrophils	B123
cancer risk prediction	B073
cancer subtypes	A029, B089
cancer-associated fibroblast	A077
cancer-associated fibroblasts	A025, B098
Cancer-associated fibroblasts	A103, B105
Cancer-Associated Fibroblasts	A035, A066
cancer-associated fibroblasts (CAF)	A021
Cancer-associated fibroblasts (CAFs)	A024
CAR T	A124
CAR T cell therapy	A104
CAR T-cell therapy	A101
care fragmentation	B061
CAR-T	A075, A089
CAR-T cell therapy	A114

American Association for Cancer Research® Special Conference in Cancer Research

**ADVANCES IN PANCREATIC CANCER RESEARCH – EMERGING
SCIENCE DRIVING TRANSFORMATIVE SOLUTIONS**

September 28–October 1, 2025 | Boston, MA



**ADVANCES IN PANCREATIC CANCER
RESEARCH – EMERGING SCIENCE
DRIVING TRANSFORMATIVE SOLUTIONS**

September 28–October 1 | Boston, MA

AACR

American Association
for Cancer Research®


2505001F

CD40	A086
CDC25C	A056
CDKN2A-ARF	A030
Cell cycle	B017
cell cycle pathway	B078
Cell state plasticity	B120
Cell surface targets	B057
cellular senescence bypass	A077
cellular stress	A053
Cellular therapy	IA01
CEND-1	A070
cfDNA methylation	A018
cGAS-STING	B029
Chemoimmunotherapy resistance	B006
chemokines	A095
chemoresistance	B129
Chemoresistance	A062, A079
Chemoresistance mechanisms	B050
chemotherapy	A115, B027, B079
Chemotherapy	B080
chemotherapy resistance	B095
Chemotherapy-associated liver damage	A010
choline pathway	A078
Chromosome loss	A004
CLDN18.2	A089
Clinical translation	B100
Clinical trial	B002
clonal evolution	B129
Clonal hematopoiesis	B081
Clonal T cell expansion	A125
CLR 225	B032
Coagulation	A120
Coagulation-mediated fibrosis	B037
Combination therapy	A123
Combinations	A118
Combinatorial therapies	A116
computational models	A025

American Association for Cancer Research® Special Conference in Cancer Research

**ADVANCES IN PANCREATIC CANCER RESEARCH – EMERGING
SCIENCE DRIVING TRANSFORMATIVE SOLUTIONS**

September 28–October 1, 2025 | Boston, MA




copy number alteration	B129
CRISPR/Cas9	B020
CRISPR-screen	A028
Crosstalk	B127
Cryptic antigens	IA01
ctDNA	A072, A126
CX3CL1-CX3CR1	A064
cytokines	A057
Cytokines	A093

D


DNA repair	B029
Daraxonrasib	IA02, B096
ddPCR	A126
DDR, Lutetium, AsPC1	A107
DDR2	B030
Detection	B054
DHODH inhibition	A122
diagnosis	B055
digital pathology	A046
disparities	B052
Disparities	B044
DNA damage repair	B035
DNA damage response	B093
DNA repair	A088
DNMT3A	B081
drug delivery	A117, B097
Drug resistance	B020, B083
Drug Resistance	B082
dual mechanism therapy	A121

E

early detection	B064
Early detection	B117
Early Detection	B070, B071
Early diagnosis	B068
Early Progression Prediction	B090
Early-detection	B056



ECM	A054
EF response	A099
Egfr signaling, NF-kB pathway, Tgfb pathway	B009
Emavusertib	A069
EMT	A063
EMT-driven resistance	B004
Endocrine-exocrine crosstalk	A032
ENT1	A122
epigenetics	A019
Epigenetics	A016, B106
Epithelial subtypes	B116
ER	B060
ERK	A060
Etiology	B059
EV-enrichment	B056
ex vivo	B087
Ex vivo perfusion	B014
Explant	B080
extracellular matrix	A015, A042, B012, B098
extracellular matrix (ECM)	A021
Extracellular matrix (ECM)	A024
Extracellular matrix sensing	A022
Extracellular vesicles	B062
Extracellular Vesicles	A044
extrinsic-apoptosis	A067
F	
fate decisions	A029
Ferroptosis	B038
FFPE	A040, B074
Fibroblast	A023
fibroblast states	A031
Fibroblast-mediated immune exclusion	A125
Fibroblasts	A085
Fibrosis	A022
FOLFIRINOX	B005, B035
functional precision medicine	B087



G


Gastrointestinal (GI) malignancies	B076
Gem/Abraxane	A099
gemcitabine	B034
Gene delivery	B025
Genetic alterations	A012
Genetically-Engineered Mouse Models	A030
Genomic Profiling	B058
Germline Testing	B047
glucocorticoids	A053
glutamine	B012
Glycans	B125
glycocalyx	A049
Glycocalyx	A065
glycomics	A049
gMDSC	A079
Gut microbiome	B094

H


Hereditary chronic pancreatitis	A026
Heterogeneity	A127, B109
Hispanics	B043
Homologous Recombination Deficiency	B039, B047
human organoids	A013
Hyaluronic Acid	B031
Hypoxia	A047, B036

I


βIII-tubulin	A067
IL1RAP	B091
IL4	A085
Imaging mass cytometry, spatial proteomics, multi-omics	B115
IMC, sWGS, Pancreatic Cancer, PDAC, spatial, copy number, cancer	B113
Immune	B123
Immune biomarkers	A071
Immune cells	A106




Immune compartment evolution	A106
Immune evasion	A027, B108
immune microenvironment	A019, A091
Immune response	A076, A090
Immunecheckpoint blockade therapy	A109
Immunotherapy	A102
immunogenic cell death	B022
Immunomodulation	A074
Immunopeptidomics	IA01
Immunosuppression	A044, A081
Immunotherapy	A086, A096, A098, B013, B016
in vitro modelling	B042
in vivo	A089
Inflammasomes	A079
inherited susceptibility	B075
Integrin signaling	B004
Integrins	A065
Interleukin-1 receptor accessory protein	B006
Intratumoral heterogeneity	B108
IPMN	B067, B074
IPMN development	A064
IPMN, Repeat RNA	B117
iron binding	A005
Irreversible electroporation (IRE)	B014
ISRIB	A101
J	
JNK	A058
K	
KEAP1-NRF2	B083
ketogenic diet	A034
ketogenic diet, KD, MSKD	B094
KEYWORDS: KRAS inhibitor, interferon, epithelial- mesenchymal transition, TRIM22, TROP2	B026
Kirsten rat sarcoma viral oncogene homolog (KRAS)	A003
KMT2D	A035
Kras	A036



KRAS	A023, A047, A091, A095
Kras carcinogenesis	B028
KRAS G12R	A118
KRAS inhibition	B057
KRAS inhibitor	B083
KRAS inhibitor resistance	B036
KRAS inhibitors	A027
KRAS/MAPK pathway	B020
KRAS-G12Ri	B096
KRAS-mutant PDAC	B024
KRASQ61, tumor microenvironment (TME), Pancreatic cancer	B076
L	
lamellipodia	A020
Lamin A	A059
large language models	B073
Lineage tracing	B106
Lineage Tracing	B082
Lineage-Tracing	A066
Lipid raft	B032
lipidomics	B066
Liquid Biopsy	B071
Liver	A009
Liver directed therapy	B013
Liver inflammation	B013
Liver metastasis	A010, A048, A081
Long-term survivors	B046
M	
M2 macrophages	A064
machine learning	B055
Machine learning	B086
macropinocytosis	B040
MAPK	A086
mass spectrometry imaging	A015
mass spectrometry proteomics	B005
MCED	B054
Mechanobiology	A065



MEKi	B096
Mesenchymal cells	A092
metabolism	A078, B040
Metabolism	A006, B036, B127
Metastases	A027
metastasis	A020
Metastasis	A084, A092, B125
Metastasis	A063
Metastatic Pancreatic Cancer	A072
methionine sulfoxide reductase	A005
Microenvironment	A120, A127
Microenvironment; Spatial proteomics; Phenotypes	B123
Microphysiological System	B037
Mitochondria	A096, B060
Mitochondria, Oxidative stress	A128
Mitochondrial metabolism	A055
MMRd cancer	A082
Moderate hyperthermia	B017
molecular glue	B003
molecular profiling	A046
Molecular profiling	B043
molecular subtypes	B099
monoclonal antibody, ADCC, combination therapy	A017
Morphospacial	B121
mortality	B051
mouse model	A019
Mouse model	A026
mRNA	B068
multi-biomarker panel, CA19-9, PBMC	B063
Multimodal	B086
Multi-modal 'omics data integration	B128
Multimodal Predictive Modeling	B090
Multi-omic integration	B116
Multiomics	A039
multiplex staining	B110
Multiplexed imaging	B116
Multiplexed mRNA therapy	A093



**ADVANCES IN PANCREATIC CANCER
RESEARCH – EMERGING SCIENCE
DRIVING TRANSFORMATIVE SOLUTIONS**

September 28–October 1 | Boston, MA



Multiplex-proteins	B056
mutant p53	B001
MUTYH	B047
myeloid	A080
Myeloid cells	A106
Myeloid Inflammation	A113
Myeloid-stromal immunosuppression	B006

N

nab-paclitaxel	B034
Nadunolimab	B091
nanomedicine	A115, A121
Nanomedicine, KRAS, SASP, MEK inhibitor, CDK inhibitor	A119
Nanotechnology	A102
Neil2 inhibition	A041
NELFE	B033
Neoadjuvant chemotherapy	B099
Neoadjuvant chemotherapy	A087
Neoadjuvant Therapy	A070
Neoantigen	A076
Neutrophil	B127
Neutrophil extracellular traps	A037
N-glycosylation	A015
NK1R	B023
non-invasive diagnosis	B063
Notch signaling	A080
Novel nano-formulated taxoid	A074
novel small molecule inhibitor	B078
Nuclear stability	A059
Nucleotide metabolism	A122
Nutrient stress	A007


O

obesity	A034
Obesity-associated PDAC	A050
Oncogene	A112
Oncologic Emergency	B041


American Association for Cancer Research® Special Conference in Cancer Research

**ADVANCES IN PANCREATIC CANCER RESEARCH – EMERGING
SCIENCE DRIVING TRANSFORMATIVE SOLUTIONS**


September 28–October 1, 2025 | Boston, MA



oncolytic virus	B022
opioid	A042
organ-on-chip	B042
Organotropism	A048
Organotypic culture	B008
Organ-specific immunity	A084
Outcomes	B076
overcoming therapy resistance	A121
overtreatment	B067
P	
p21	B028
p53	A007
p63 regulators	A028
PANC1, bstrongomab, PARPi	A107
pancreas	A068
Pancreas	B109
Pancreas regeneration	B048
Pancreatic Adenocarcinoma	B041
pancreatic cancer	A008, B003, B051, B064, B078, B092
Pancreatic cancer	A013, A040, A074, A097, A098, B014, B016, B052, B077
Pancreatic Cancer	A041, A044, A069, B019, B070
Pancreatic Cancer Detection Consortium	B069
Pancreatic Cancer Early Detection	B069
Pancreatic cancer metastasis	A018
Pancreatic cancer organoid	B084
Pancreatic cancer progression	A002
Pancreatic cancer, chemotherapy resistance, DNA repair	A128
pancreatic cancer, extracellular matrix, fibulin	B009
Pancreatic cancer, muscle wasting, autophagy	A045
Pancreatic Cancer, Patient Support, Quality of Life, Second opinion, Advocacy	B045
pancreatic cancer, spatial proteomics, high-plex imaging	B124
Pancreatic cancer-associated fibroblasts	B050
pancreatic cyst	B066



Pancreatic Cystic Neoplasms	B071
pancreatic ductal adenocarcinoma	A034, A087, B097
Pancreatic ductal adenocarcinoma	A037, A103, A123, B043, B062, B095, B105
pancreatic ductal adenocarcinoma	A105
Pancreatic ductal adenocarcinoma (PDAC)	A003, A071, B038
Pancreatic ductal adenocarcinoma, early detection, immune cell gene expression	B063
Pancreatic ductal adenocarcinoma, KRAS, drug resistance	A017
Pancreatic ductal adenocarcinoma, PDAC	B094
Pancreatic ductal adenocarcinoma; Hypoxia; IL-17RA; Aptamer	A002
Pancreatic Neoplasms	B058
pancreatic stellate cells	A090
Pancreatic tumor microenvironment	A055
pancreatitis	A057
PanIN	A046
PanIN to PDAC progression	A031
PAR1 inhibition	B037
PARP Inhibitor	B039
PARP/PD-1 blockade	A125
PARPi resistance	B093
Patient derived organoid	B095
Patient-derived organoid co-culture	B050
patient-derived xenografts	B005
PD-1	A082
PDAC	A009, A039, A081, B055, B091, B101, B104
PDAC genetics	B044
PDAC Subtype Classification	A043
PDAC therapeutics	B033
Personalization	B080
Personalized therapy	B008
Phase 1 trial	A071
Phase 3 Pancreatic Cancer High Risk Cohort Biobank	B069
Phenformin	A096
Photodynamic Therapy	B019




Pin1 degrader	B077
plasma, ctDNA, pancreatic cancer	B072
Plasminogen	A120
Plasticity	B107, B118, B122
Platinum resistance	A098
plerixafor	A117
POLQ	A088
Polymeric nanoparticles	B025
polytherapy	B040
PRC1	A056
Precision Immunotherapy	A088
Precision medicine	A095
Precision oncology	B008
Preclinical drug development	B077
Preclinical model	B084
Preclinical model.	A062
Premetastatic niche	A023
preventative medicine	B064
Prevention	B059
Proglumide	A114
Prognosis	B086
PROTAC	A112
PROTACs	A108
proteolysis	A045
Proteomics	B059
Proteostasis	A036
PS101	A068

Q

There were no keywords in this range.

R

Radiomics and Biomarker Integration	B090
RAGE	A097
RAS inhibition	B097, B120
RAS Inhibition	B082
RAS inhibitor	A006
RAS inhibitor sensitization	B004



**ADVANCES IN PANCREATIC CANCER
RESEARCH – EMERGING SCIENCE
DRIVING TRANSFORMATIVE SOLUTIONS**

September 28–October 1 | Boston, MA

AACR

American Association
for Cancer Research®


2505001F

RAS inhibitors	B092
RAS pathway inhibition	B038
RAS(ON)	IA02
RAS(ON) inhibition	A118
RAS-targeted therapy resistance	A077
Reactive oxygen species	A037
Recurrence risk	A051
Regulatory Network Analysis	A047
renal failure	B051
Repurposing	B023
Resectable Pancreatic Cancer	A070
Resistance	A006
Risk Factors, Mouse Models, Tumor Suppressor	A033
RNA binding protein	A029, B089
RNA splicing	A060
RNA therapeutics	B025
RNA therapy	A100
RTK	B030
S	
Scaffold protein	A058
Screening	B054
scRNA-seq	B074
Selectivity	A112
Serpin B9	A102
SF3B1, RBM10, p53	A004
SHP2 ProTAC	B024
Single cell omics	B120
single-cell	B126
Single-cell	A009
Single-cell transcriptomics	A082
Small drug molecule	B030
SMNDC1	A060
snRNA-seq Atlas	A050
Sonic Hedgehog	B098
sonidegib	A117
Spatial features	A051
spatial heterogeneity	B110


American Association for Cancer Research® Special Conference in Cancer Research

**ADVANCES IN PANCREATIC CANCER RESEARCH – EMERGING
SCIENCE DRIVING TRANSFORMATIVE SOLUTIONS**


September 28–October 1, 2025 | Boston, MA



Spatial proteomics	B128
spatial transcriptomics	B011, B126
Spatial transcriptomics	B100, B118
Spatial Transcriptomics	A052, B117
splicing	A020
Spontaneous Tumor Lysis Syndrome (sTLS)	B041
STAT3 signaling	A103
Stemness	A108
Stereotactic radiotherapy	B099
steroid receptor	A053
Stroma	A123
Stromal compartment	A024
sumoylation	B027
Support groups, Patient Navigation, Mentoring, Patient Mentor	B045
survival disparity	B061
survival motor neuron domain containing 1 (SMNDC1)	A003
Syndecan-1, nutrient scavenging, macropinocytosis	A017
synergy	B027
Synthetic lethality	B028
Systemic metabolic disorders	A032
T	
thromboembolism	B052
T cells	A091
TAK1	B029
target identification	B089
Targeted delivery	A100
targeted radiotherapy	B032
Targeted therapies	B107
targeted therapy	B003, B111
Targeting KRAS	A116
Tertiary lymphoid structures	A087, A094
TGF- β	A012
TGM2	A012
therapeutic resistance	B092
Therapeutic Resistance	B122
Therapeutic strategies	B031



Therapy resistance	B057, B103
thymidine analogue	B001
TIGIT; immune suppression; KMT2D	A061
Timp1	A010
tissue engineering	B012
TLS	A099
TME	B100
TMEM240	A018
TNFR-MK2 signaling	B101
tobacco smoking	B075
TP53 knockout	A013
TRAIL	A067
Transcription factors	B107
Transcriptional heterogeneity	B102
Transcriptional plasticity	B103
Transcriptional Regulation	A043
Transcriptional reprogramming	A062
transcriptional subtyping	B111
Transcription-replication conflict	A041
Transitional Cell State	B122
TRD209	B024
triple-drug therapeutic strategy	B001
TTFIELDS	B034, B035
Tumor Evolution	A052
Tumor heterogeneity	B125
tumor heterogeneity, biomarker discovery, therapeutic innovation,	B124
Tumor immune activation	A100
Tumor immunity	A094
Tumor initiation	B106
tumor macrophages	A078
Tumor metabolism	A032
Tumor micro environment (TME)	A114
tumor microbiome	B011
Tumor microenvironment	A097
Tumor Microenvironment	B019
tumor microenvironment	A021, A042, A080, A105, B011, B110



Tumor microenvironment	A014, A048, A051, A076, A083, A092, B002, B031, B042, B046, B105, B118, B128
Tumor Microenvironment	A030, A066, A108, A113
tumor microenvironment Immunesuppression	A109
tumor microenvironment, antigen-presenting cancer- associated fibroblast, regulatory T cells	B009
tumor microenvironment, custom pipeline, bio- informatic workflow	B124
tumor progression	A084
Tumor Suppressors	A043
Tumor-associated antigens (TAAs)	A093
Tumor-associated macrophages	A055
tumor-associated macrophages	A105
tumorigenesis	B109
tumor-initiating cells	B119
Tumour microenvironment	A040, B115
Tumour, Immune, Stroma	B115
Type 2 Helper T cells	A085
Tyro3	A083
U	
UHRF1	A016
UNC5B	A063
untreated pancreatic cancer	B061
V	
vaccine	A124
Vascular	A127
Visceral Adipose Tissue	A050
Vitamin B3 derivatives, NAD+ precursors	A128
W	
WDR-62	A058
Whole Blood	B068
whole genome sequencing, cfDNA	B072
Wild-Type IDH1	B039
X	

There were no keywords in this range.

Y

There were no keywords in this range.

Z

zoldonrasib

IA02